Facebook
Twitter
LinkedIn
Forward
2023 Spring Annual Meeting
Target Audience
The education design of this activity addresses the needs of physicians and scientists in the field of pediatric, perinatal and general pathology who are involved in the diagnosis and/or treatment of pediatric patients with pathologic disorders.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss recent advances in the field of pediatric pathology that impact research and practice.
- Cite 2-3 examples of new information on the underlying etiologies and mechanisms of pediatric and perinatal diseases.
- Explain how to translate the latest developments in pediatric and perinatal pathology into clinical practice.
Disclosure Information
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Pediatric Pathology does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Disclosure Information:
The Society for Pediatric Pathology (SPP) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by SPP are required to disclose all financial relationships with any ineligible company within the past 24 months to the SPP. All financial relationships reported are identified as relevant and mitigated by the SPP in accordance with the Standards for Integrity and Independent in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by the SPP Education Committee to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by the SPP.
Planners and Managers
The following planners and managers have no relevant financial relationships with ineligible companies:
Caitlin Alexander, Carlye Armstrong, Jenna Bodmer, Fang Bu, Athena Chen, Amy Coffey, Lyndsay Cole, Sandy Cope-Yokoyama, Mike Covinsky, Dina El Demellawy, Linda Ernst, Julie Fanburg-Smith, Laura Finn, Shipra Garg, Ahmed Gilani, Deb Heller, Shannon Kelley, Selene Koo, Alexandra Kovach, Chandra Krishnan, Anna Lee, Jiancong Liang, Oscar Lopez-Nunez, Rachel Mariani, Melissa Marick, Terry Morgan, Anita Nagy, M. Cristina Pacheco, William Parks, Lauren Parsons, Jennifer Pogoriler, Sarah Porter, Juan Putra, Shahrazad Saab, Ali Saad, Claudia Salgado, Chris Sande, Teresa Santiago, Consolato Sergi, Bradford Siegele, Sam Sirotnikov, Lea Surrey, Serena Tan, Jeff Terry, Amy Treece, Jose Velazquez-Vega, Dehua Wang, Huiying Wang, Larry Wang, Ben Wilkins, Hao Wu, Zhongxin Yu, Shengmei Zhou
The following planners and mangers have the following relevant financial relationships with ineligible companies:
| Name | Disclosure |
Karen Chisholm | Stock Shareholder: Illumina |
Jessica Davis | Consulting Fee: Bayer Pharmaceuticals; Honoraria: Bayer Pharmaceuticals, Aadi Bioscience |
Faculty, Authors, Content Developers
The following faculty, authors, and content developers have no relevant financial relationships with ineligible companies:
Alyaa Al-Ibraheemi, FNU Alnoor, Alicia Andrews, Andrea Bakker, Erin Barletta, Lara Berklite, Laura Biederman, Kevin Bove, Andrea Breaux, Carlos Casiano, Rush Chewning, Stephanie Collier, Mike Covinsky, Randall Craver, Julieta D'Ardis, Ronald de Krijger, Shipra Garg, Catherine Gestrich, Ahmed Gilani, Ivan Gonzalez, Arin Greene, Cristo Jose Guardado Salazar, Anita Gupta, Phoebe Hammer, Jacob Havens, Douglas Hawkins, Annette Hebert, Amer Heider, Philip Katzman, Charlotte Kim, Selene Koo, Harry Kozakewich, Lauren Kroll-Wheeler, Kyle Kurek, Anna Lee, Brian Lockhart, Oscar Lopez-Nunez, Jiajie Lu, Kaitlin Machina, Shamlal Mangray, Elizabeth McLeod, Terry Morgan, Paula North, He Zhen Ren, Carine Renner, Ashlie Rubrecht, Phassawan Rungsiprakarn, Louis Samson, Archana Shenoy, Bradford Siegele, Sam Sirotnikov, Gino Somers, Jerzy Stanek, Matthew Stark, Jasmine Steele, Kaitlin Weaver, Ben Wilkins, Paul Zamiara
The following faculty, authors and content developers have the following relevant financial relationships with ineligible companies:
| Name | Disclosure |
Denise Adams | Consulting Fee: Novartis, Nobias |
Moderators
The following moderators have no relevant financial relationships with ineligible companies:
Alexandra Kovach, Sarangarajan Ranganathan, Amelia Sybenga, Naseem Uddin, Jose Velazquez-Vega, Ben Wilkins
The following moderators reported the following relevant financial relationships with ineligible companies:
| Name | Disclosure |
Jason Jarzembowski | Contracted Research: Merck & Co., Inc. |
Content Reviewers
The following content reviewers have no relevant financial relationships with ineligible companies:
Lauren Parsons
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Physician Accreditation Statement
The Society for Pediatric Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
The Society for Pediatric Pathology designates this Other activity (blended live activity and enduring material) for a maximum of 8.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Pathology (ABPath) Continuous Certification
This activity is registered for American Board of Pathology Lifelong Learning (CME) credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to satisfy the Lifelong Learning (CME) requirements in the American Board of Pathology’s (ABPath) Continuous Certification (CC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for purpose of granting credit.
Successful completion of the CME activity allows the participant to earn up to 8.75 Lifelong Learning (CME) credits.
To receive credit, you must complete the evaluation and provide your ABPath Diplomate ID and Date of Birth (MM/DD). Your information will be shared with the ABPath through the ACCME Program and Activity Reporting System (PARS).
Instructions to Receive CME Credit
All attendees should complete the session specific evaluations as related to those portions of the 2023 Spring Annual Meeting that were attended, as well as the overall conference evaluation. You must be logged into EthosCE in order to access the evaluations and claim credit. You must claim credit by June 20, 2023.
The chart below outlines which portions of the 2023 Spring Annual Meeting are offered for CME credit and the maximum number of credit hours a physician can earn for each portion accredited for AMA PRA Category 1 Credit™. As this is an “Other activity” format you may claim credit based on your attendance at either the live session or for watching the recorded session up through April 20, 2023 when recorded content will expire. However, you may not claim credit more than once for a given session. Those sessions that were recorded are marked with an asterisk (*).
Activity | CME Credit Hours |
*Farber-Landing Lecture | 1.0 |
Platform I | 1.0 |
Platform II | 1.0 |
Platform III | 1.0 |
Poster Blitz | 1.25 |
*Symposium: Vascular Malformations and Tumors | 3.5 |
Total | 8.75 |
Contact Information
For questions regarding the accreditation of this meeting and the process for completing the evaluations and claiming credit, please contact the SPP’s Accredited CE Coordinator, Sarah Porter, via email at sporter@aoeconsulting.com or via phone at: (303) 557-0859 Ext. 84.
Available Credit
- 8.75 AMA PRA Category 1 Credit™
- 8.75 Participation Credit(s)